Bristol Myers Squibb (BMY)
(Delayed Data from NYSE)
$48.11 USD
+0.49 (1.03%)
Updated Aug 23, 2024 04:00 PM ET
Pre-Market: $48.12 +0.01 (0.02%) 8:16 AM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$48.11 USD
+0.49 (1.03%)
Updated Aug 23, 2024 04:00 PM ET
Pre-Market: $48.12 +0.01 (0.02%) 8:16 AM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage
by Zacks Equity Research
Shares of Athersys, Inc. (ATHX) surged significantly in the post market trading on Mar 28 after research firm William Blair initiated a coverage on the stock with an outperform rating.
Bristol-Myers (BMY) Opdivo Gets Positive CHMP Opinion
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the CHMP has recommended the approval of immunotherapy Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults.
Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved
by Arpita Dutt
This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.
Infinity Pharma Focuses on Cancer Drug: Competition Looms
by Zacks Equity Research
We issued an updated research report on Infinity Pharmaceuticals, Inc. (INFI) on Mar 20, 2017.
Bristol-Myers Squibb and CytomX Therapeutics Extend Deal
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) and CytomX Therapeutics, Inc. (CTMX), announced an expansion of their 2014 strategic collaboration to discover novel therapies.
6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017
by Zacks Equity Research
Glaxo carries a Zacks Rank #2 (Buy).
Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.
Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs
by Sweta Killa
President Donald Trump March 7 tweet on increasing competition and lowering drug prices sent fresh shockwaves across the industry.
Repros (RPRX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) is expected to report fourth-quarter 2016 results this month.
Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report fourth-quarter 2016 results this month.
AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's in Store?
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) is expected to report fourth-quarter 2016 results this month.
What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?
by Zacks Equity Research
Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.
Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?
by Zacks Equity Research
Celldex Therapeutics, Inc. (CLDX) is expected to report fourth-quarter 2016 results on Mar 4 after market close.
Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4
by Zacks Equity Research
Nektar Therapeutics (NKTR) reported loss of 28 cents per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of loss of 26 cents.
Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4
by Zacks Equity Research
Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.
Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) is expected to report fourth-quarter 2016 results on Mar 7.
Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y
by Zacks Equity Research
Exelixis, Inc.(EXEL) posted fourth-quarter 2016 earnings of 12 cents, compared with loss of 18 cents per share in the year ago quarter.
Bristol-Myers (BMY) Up 20.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs
by Arpita Dutt
Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.
Bristol Myers' Future Unsure as Carl Icahn Takes Stake
by Joseph Lu
Could Bristol-Myers Squibb Company (BMY) soon be put on the market for sale as activist investor, Carl Icahn, takes interest in the company?
Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?
by Zacks Equity Research
Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.
Can Carl Icahn Save Bristol Myers Squibb?
by Joseph Lu
Bristol-Myers Squibb Company (BMY) experienced slight growth after Carl Icahn, billionaire activist-investor, reportedly wants to take stake in the company.
Pharma Stock Roundup: Merck's Alzheimer's Study Halted, Allergan to Buy ZELTIQ
by Arpita Dutt
The main news this week was an update from Merck (MRK) regarding its Alzheimer's disease drug.
Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi
by Arpita Dutt
Key highlights this week include earnings results from Allergan (AGN) and Glaxo, Sanofi's update regarding Praluent and Teva's ongoing woes.
Gilead (GILD) Beats Q4 Earnings & Sales, View Disappoints
by Zacks Equity Research
Gilead Sciences' (GILD) fourth quarter results beat on both earnings and sales but the guidance for 2017 was quite disappointing.